Post-Artesunate Delayed Hemolysis: A Review of Current Evidence

Area of Science:

• Malariology
• Hematology
• Pharmacology

Background:

• Artesunate is the primary treatment for severe malaria.
• Post-artesunate delayed hemolysis (PADH) is an infrequent adverse event.
• PADH predominantly affects non-immune travelers.

Purpose of the Study:

• To elucidate the pathophysiology of PADH.
• To inform clinicians about the timing and presentation of PADH.
• To emphasize the importance of hematological monitoring post-artesunate treatment.

Main Methods:

• Review of clinical presentations and proposed mechanisms of PADH.
• Analysis of the "pitting" hypothesis for red blood cell clearance.
• Correlation of artesunate treatment with delayed hemolytic anemia.

Main Results:

• PADH is characterized by "pitting" of red blood cells in the spleen after artesunate treatment.
• Affected red blood cells have reduced lifespan (7-21 days), causing anemia 7+ days post-treatment.
• No fatal cases of PADH have been reported, and benefits of artesunate outweigh risks.

Conclusions:

• PADH is a recognized, albeit uncommon, adverse event following artesunate therapy for severe malaria.
• Understanding PADH pathophysiology aids in early detection and management.
• Clinical vigilance and hematological follow-up are crucial for patients treated with artesunate.